language English
Article 2026 · 0 atıf

Breaking the vicious cycle: Avasopasem manganese disrupts ER Stress-Oxidative damage crosstalk in ischemic cardiac injury in type 1 diabetic mice

Kutlu, Zerrin, Halici, Zekai, Tavaci, Taha, Karcioglu, Saliha Sena, Yildirim, Serkan, Bayraktutan, Zafer, Celik, Zeynep

Özet

This study aimed to investigate the effects of avasopasem manganese (AVA), a superoxide dismutase (SOD) mimetic, on endoplasmic reticulum stress (ERS) in isoproterenol (ISP)-induced ischemic heart injury in type 1 diabetic male mice. Oxidative stress (OS) and ERS are known to play important roles in the progression of cardiac damage, and diabetes mellitus (DM) itself exacerbates ERS. It is postulated that agents capable of inhibiting ERS many alleviate ischemic heart injury. This study investigated the effects of AVA on ischemic heart injury in type 1 diabetic mice via ERS-related proteins (GRP78, PERK, IRE1, ATF4, XBP1, Nrf2, and CHOP/caspase 12). A power analysis determined that 96 male BALC-c mice, aged 6-8 weeks, were utilized and randomly allocated into six groups: control, DM, ISP, DM + AVA (10 mg/kg), ISP + AVA (10 mg/kg), and DM + ISP + AVA (10 mg/kg). In diabetic and ischemic mice, AVA treatment raised the levels of glutathione (GSH) and the activities of the enzymes superoxide dismutase (SOD) and catalase (CAT). It also lowerd the levels of malondialdehyde (MDA) and the activity of myeloperoxidase (MPO). Cardiac markers creatine kinase-muscle type/brain type isoenzyme (CK-MB) and cardiac troponin T (cTnT) levels were also decreased following treatment. In the diabetic and ischemic mice, mRNA expression of ERSrelated proteins (GRP78, PERK, IRE1, ATF4, XBP1, and Nrf2) was elevated but significantly reduced after AVA administration. AVA treatment improved cardiac outcomes by reducing OS and inflammation and downregulating ERS-related protein expression in diabetic and ischemic mice.

Anahtar Kelimeler
ATF4 Avasopasem manganese GRP78 cTnT Nrf2 PERK CARDIOMYOPATHY ASSAY ACID
WoS Kategorileri
Pharmacology & Pharmacy
Sürdürülebilir Kalkınma Amaçları
Künye
Dergi
EUROPEAN JOURNAL OF PHARMACOLOGY
Yıl
2026
Cilt
1011
ISSN
0014-2999
eISSN
1879-0712
DOI
10.1016/j.ejphar.2025.178423
WoS UID
WOS:001641222800001
Yayını aç (DOI)